Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Xeloda Combo With Taxotere Approved; Phase IV Dosing Study Planned

Executive Summary

Roche will submit the protocol for a Phase II study comparing three different dose regimens for Xeloda (capecitabine) by January 2002 as one of its postmarketing commitments following the Sept. 7 supplemental approval of the agent for use in combination with Aventis' Taxotere (docetaxel) to treat metastatic breast cancer.

You may also be interested in...



Xeloda-Warfarin Black Box Warning To Be Subject Of Roche Letter To Doctors

Roche is preparing a letter to physicians highlighting a black box warning about interactions between Xeloda (capecitabine) and warfarin following FDA's Sept. 7 approval of the labeling change.

Xeloda-Warfarin Black Box Warning To Be Subject Of Roche Letter To Doctors

Roche is preparing a letter to physicians highlighting a black box warning about interactions between Xeloda (capecitabine) and warfarin following FDA's Sept. 7 approval of the labeling change.

Roche Xeloda Colorectal Use Clears FDA; Promotions Must Cite Camptosar

Roche will study Xeloda in combination with Pharmacia's Camptosar in colorectal cancer patients following FDA approval of Xeloda April 30 for use in metastatic colorectal cancer patients.

UsernamePublicRestriction

Register

PS038514

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel